ClinicaliQ Trial Snapshot
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors — Active Not Recruiting • Phase III • NCT04432584.
- Crovalimab was as safe and effective as eculizumab in treating PNH patients already on complement inhibitor therapy.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A study designed to evaluate the safety of crovalimab with eculizumab in participants with PNH currently treated with complement inhibitors. This study will enroll approximately 190 participants. Conditions: Paroxysmal Nocturnal Hemoglobinuria Interventions: Crovalimab, Eculizumab Lead Sponsor: Hoffmann-La Roche Planned Enrollment: 190 participants